Quince Therapeutics (NASDAQ:QNCX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX) in a research note released on Thursday,Benzinga reports. They currently have a $12.00 target price on the stock.

QNCX has been the subject of a number of other research reports. Maxim Group assumed coverage on Quince Therapeutics in a report on Thursday, November 7th. They issued a “buy” rating and a $6.00 price target for the company. EF Hutton Acquisition Co. I upgraded Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 22nd. Rodman & Renshaw assumed coverage on Quince Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $11.00 price target for the company. RODMAN&RENSHAW raised shares of Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 29th. Finally, Brookline Capital Management assumed coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price objective for the company. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Quince Therapeutics has an average rating of “Buy” and a consensus price target of $9.50.

Quince Therapeutics Stock Up 3.7 %

Shares of NASDAQ QNCX opened at $1.95 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. The firm has a market capitalization of $85.80 million, a price-to-earnings ratio of -1.57 and a beta of 0.74. The stock has a 50 day moving average price of $1.80 and a 200 day moving average price of $1.11. Quince Therapeutics has a 52-week low of $0.51 and a 52-week high of $2.45.

Hedge Funds Weigh In On Quince Therapeutics

An institutional investor recently raised its position in Quince Therapeutics stock. Geode Capital Management LLC raised its holdings in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 339,125 shares of the company’s stock after purchasing an additional 66,170 shares during the period. Geode Capital Management LLC owned 0.78% of Quince Therapeutics worth $263,000 at the end of the most recent quarter. 30.75% of the stock is owned by institutional investors.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.